Resources
Get helpful information about MRD and M-inSight®
All
Articles
Documentation
Events
Posters
Publications
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020
Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies - J Proteome Res. 2018
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM - Clin Chem. 2021
Multiple Myeloma MRD Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow - Clin Chem. 2021
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry - Blood Cancer J. 2023
IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020
